Acthar Gel

Drug Overview

In the highly specialized field of Endocrinology, managing the complex interplay between the brain and the adrenal glands is essential for treating systemic inflammatory and neurological conditions. Acthar Gel is a highly purified preparation of adrenocorticotropic hormone (ACTH). Classified as an ACTH Analog, it occupies a unique space in Targeted Therapy by stimulating the body’s natural pathways rather than simply providing a synthetic substitute.

Acthar Gel is a long-acting, porcine-derived Biologic designed for controlled release. Unlike rapid-acting synthetic steroids, this medication works as a “stimulator,” prompting the adrenal cortex to produce a balanced profile of endogenous Corticosteroids, including cortisol, corticosterone, and aldosterone. This nuanced approach helps modulate the immune response and manage acute exacerbations of chronic diseases.

• Generic Name: Repository Corticotropin Injection
• US Brand Names: H.P. Acthar Gel
• Drug Class: ACTH Analog (Adrenocorticotropic Hormone)
• Drug Category: Endocrinology / Neurology / Rheumatology
• Route of Administration: Intramuscular (IM) or Subcutaneous (SC) injection
• FDA Approval Status: FDA-approved for various indications, including infantile spasms, multiple sclerosis exacerbations, and specific rheumatic or inflammatory disorders.

What Is It and How Does It Work? (Mechanism of Action)

The functionality of Acthar Gel is rooted in its role as a key messenger in the Hypothalamic-Pituitary-Adrenal (HPA) Axis. To understand its efficacy, one must look at how it interacts with cellular receptors across multiple organ systems.

Adrenal Stimulation

At the primary molecular level, Acthar Gel binds to the Melanocortin Receptor Type 2 (MC2R) located on the surface of the adrenal cortex. This binding activates an enzyme called adenylate cyclase, which increases the production of cyclic AMP (cAMP). This chemical signal triggers the rate-limiting step in steroidogenesis: the conversion of cholesterol into pregnenolone. The result is the endogenous secretion of a full spectrum of steroid hormones. Because it mimics the natural signaling of the pituitary gland, it provides a more physiological “pulse” of hormones than exogenous oral steroids.

Extra-Adrenal Effects

Beyond the adrenal glands, Acthar Gel is thought to have direct effects on the immune system through other Melanocortin Receptors (MCRs), specifically MC1R, MC3R, MC4R, and MC5R. These receptors are found on immune cells (like macrophages and B-cells) and within the central nervous system. By binding to these receptors, the drug may directly down-regulate pro-inflammatory cytokines and assist in the “calming” of an overactive immune system, which is particularly relevant in treating neurological inflammation and infantile spasms.

FDA-Approved Clinical Indications

Primary Indication

The primary therapeutic focus for Acthar Gel involves two distinct patient populations:

1. Infantile Spasms (IS): Used as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age.
2. Multiple Sclerosis (MS): Administered for the treatment of acute exacerbations of multiple sclerosis in adults, often when standard high-dose corticosteroids are ineffective or poorly tolerated.

Other Approved & Off-Label Uses

While it is an Endocrinology product by classification, its utility spans several systemic inflammatory categories:

• Primary Endocrinology Indications:
  • Diagnostic Testing: Evaluation of adrenocortical function (though synthetic cosyntropin is more common for this purpose).
  • Adrenal Insufficiency Management: In specific cases where stimulation of existing adrenal tissue is preferred over Hormone Replacement Therapy.
• Rheumatic Disorders: Psoriatic arthritis, Rheumatoid arthritis, and Ankylosing spondylitis.
• Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye.
• Dermatologic Diseases: Stevens-Johnson syndrome and severe erythema multiforme.
• Nephrotic Syndrome: To induce a remission of proteinuria in nephrotic syndrome without uremia.

Dosage and Administration Protocols

Because Acthar Gel is a Hormone stimulator, dosage is highly individualized based on the patient’s age, weight, and the severity of the condition. Titration is critical to prevent “rebound” symptoms or excessive adrenal suppression.

Indication	Standard Dose	Frequency
Infantile Spasms	75 units/m² (BSA)	Twice daily (IM injection) for 2 weeks
Infantile Spasms (Taper)	Gradual reduction	Over a 2-week period following initial treatment
MS Exacerbation	80 to 120 units	Daily (IM or SC) for 2 to 3 weeks
Nephrotic Syndrome	40 to 80 units	Every 24 to 72 hours

Administration Notes

• Titration: For infantile spasms, a strict 4-week protocol is usually followed (2 weeks of full dose, 2 weeks of tapering).
• Timing: For MS and rheumatic conditions, doses are typically given in the morning to align with the body’s natural circadian rhythm of cortisol release.
• Renal/Hepatic: No specific dose adjustments are mandated in the label, but close monitoring of electrolytes is required as ACTH increases aldosterone, which can lead to fluid retention.

Warning: Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Recent clinical research (2020–2026) has focused on the drug’s long-term impact on developmental outcomes in infants and relapse rates in MS patients.

Infantile Spasms Data

In pivotal studies, Acthar Gel demonstrated high efficacy in achieving “clinical disappearance” of spasms. Numerical data indicates that up to 80% to 90% of patients achieved complete cessation of spasms within the first two weeks of therapy. Furthermore, electroencephalogram (EEG) results often show a resolution of hypsarrhythmia (a chaotic brain wave pattern) in a significant majority of responders, which is a key biochemical target for preventing long-term cognitive impairment.

Multiple Sclerosis (MS) Outcomes

In the realm of MS exacerbations, research has compared Acthar Gel to traditional intravenous methylprednisolone (IVMP). Clinical trials have shown that for “steroid-resistant” patients—those who do not respond to IVMP—approximately 60% to 70% showed significant improvement in their Expanded Disability Status Scale (EDSS) scores after a course of repository corticotropin. This suggests that the extra-adrenal melanocortin signaling provides an additive benefit over simple glucocorticoid receptor activation.

Safety Profile and Side Effects

Black Box Warning: There is currently no Black Box Warning for Acthar Gel. However, it is subject to the same precautions as any potent systemic corticosteroid therapy.

Common Side Effects (>10%)

• Increased Appetite and Weight Gain: Due to the metabolic effects of increased cortisol.
• Infections: Increased risk of viral or bacterial infections due to immunosuppression.
• Insomnia and Irritability: Particularly common in pediatric patients (“steroid rage”).
• Fluid Retention: Resulting in puffiness or “moon face” (Cushingoid features).
• Hypertension: Elevated blood pressure due to mineralocorticoid activity.

Serious Adverse Events

• Adrenal Insufficiency: Occurs if the drug is stopped abruptly (HPA axis suppression).
• Severe Hypertension: Risk of hypertensive encephalopathy in infants.
• Gastrointestinal Perforation: Specifically in patients with underlying bowel issues.
• Hypokalemia: Dangerously low potassium levels.
• Masking of Infection: The drug may hide symptoms of a serious illness until it is advanced.

Management Strategies

Pediatric patients must undergo regular blood pressure checks and electrolyte monitoring. For all patients, a “Sick Day Protocol” is essential; if the patient develops a fever or undergoes surgery, the medical team must be notified immediately as the body’s stress response may be compromised.

Research Areas

Direct Clinical Connections

Active research in 2024–2026 is investigating the Pancreatic Beta-cell Preservation potential of melanocortin agonists. There is evidence that MCR signaling may reduce oxidative stress in the pancreas, potentially slowing the progression of certain autoimmune-driven metabolic shifts. Additionally, studies are looking at the drug’s effect on Osteoblast/Osteoclast Activity. While long-term use can lead to bone thinning (osteoporosis), short-term pulse therapy is being studied to see if the endogenous nature of the hormone release is less damaging to bone than synthetic alternatives.

Generalization and Novel Delivery

The field is moving toward Novel Delivery Systems, including the potential for auto-injector pens that make home administration easier for MS patients with limited manual dexterity. There is also significant work on the development of synthetic ACTH analogs that are more selective for MC1R and MC3R to provide anti-inflammatory benefits without the metabolic side effects of stimulating the adrenal glands (MC2R).

Disclaimer: Information regarding the use of Acthar Gel for Pancreatic Beta-cell Preservation and the development of highly selective synthetic ACTH analogs for non-adrenal inflammation is considered investigational as of 2026. While these represent major frontiers in biologics research, they are not yet standard clinical practice for all patient populations.

Severe Disease & Prevention

Research continues into the drug’s role in preventing the “epileptic encephalopathy” that follows uncontrolled infantile spasms. By rapidly achieving biochemical targets in the brain, clinicians aim to prevent the microvascular and neuronal damage that leads to permanent developmental delays.

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before the first dose, a comprehensive baseline must be established:

• Baseline Diagnostics: Fasting glucose, HbA1c, and an electrolyte panel (Sodium, Potassium, Calcium).
• Organ Function: Renal function (eGFR) and baseline blood pressure.
• Specialized Testing: A baseline EEG for infantile spasm patients.
• Screening: Rule out latent infections such as Tuberculosis (TB) or Hepatitis through screening panels.

Monitoring and Precautions

• Vigilance: Monitor for “therapeutic escape,” where the condition begins to flare during the taper phase.
• Growth: In pediatric patients, linear growth and head circumference must be tracked monthly.
• Lifestyle: For adults, Medical Nutrition Therapy (MNT) focusing on low-sodium and high-potassium intake is recommended to combat fluid retention. Consistent, low-impact exercise is encouraged to support bone health.

“Do’s and Don’ts” (Actionable for Metabolic Health)

• DO keep a precise log of injection times and any changes in symptoms or behavior.
• DO ensure the patient is up to date on non-live vaccines before starting treatment.
• DON’T stop the medication suddenly; the taper is vital to allow the pituitary gland to “wake up.”
• DON’T use the gel if it has been frozen or contains large particles.

Legal Disclaimer

This medical information is provided for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. HP Acthar Gel is a potent medication that must be used only under strict medical supervision by an experienced specialist.